14 min listen
What Clinicians Want to Know About Toxicity Considerations Associated with BTK Inhibitors
What Clinicians Want to Know About Toxicity Considerations Associated with BTK Inhibitors
ratings:
Length:
63 minutes
Released:
Sep 22, 2023
Format:
Podcast episode
Description
Dr Nicole Lamanna from the Columbia University Herbert Irving Comprehensive Cancer Center in New York, New York, and Dr William G Wierda from The University of Texas MD Anderson Cancer Center in Houston, Texas, discuss the spectrum of toxicities associated with BTK inhibitors and strategies for their mitigation and management for patients with chronic lymphocytic leukemia and mantle cell lymphoma, moderated by Dr Neil Love. Produced by Research To Practice.
CME information and select publications here (https://www.researchtopractice.com/BTKToxicities23)
CME information and select publications here (https://www.researchtopractice.com/BTKToxicities23)
Released:
Sep 22, 2023
Format:
Podcast episode
Titles in the series (100)
Dr Kathleen Moore Comments on the Management of Ovarian Cancer During the COVID-19 Pandemic: Dr Kathleen Moore from the Stephenson Cancer Center and co-chair of the SGO 2020 Annual Meeting discusses COVID guidelines and the impact of the pandemic on clinical research and the treatment of ovarian cancer. by Oncology Today with Dr Neil Love